The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Interim Report January – June 2026
The Group in summary THE GROUPAPRIL – JUNEJAN – JUNEFULL YEAR 20262025202620252025Net sales6 239 7 012 9 613 11 586 20 087Operating loss-20 579 -18 611 -42 807 -32 148 -83 501Result after financial items-20 141 -17...Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac
Intervacc AB (publ) today announces that it has submitted a Type II variation application to the European Medicines Agency (EMA) for Strangvac®, the company’s innovative vaccine against strangles in horses. The application seeks to extend the stated duration of...Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit
Intervacc AB (publ) today announces that Strangvac®, the company’s innovative vaccine against strangles in horses, has been approved for import into New Zealand under a Special Circumstances Permit. The approval follows a request from the New Zealand Equine Health...Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials
Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, has completed the evaluation of a US strain of Streptococcus equi in US horses prior to its use in a clinical trial towards the registration of Strangvac®, a vaccine against equine...Emil Billbäck appointed new Chair of the Board of Intervacc
Intervacc AB (publ), a growth company within veterinary medicine with its vaccine Strangvac® registered in 16 European countries, today announces that Chairman of the Board Håkan Björklund has handed over to Emil Billbäck, previously a Board member, who was elected as...Nyhetstjänster
